Gain Therapeutics’ (GANX) Buy Rating Reiterated at Chardan Capital
Chardan Capital restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a report published on Friday morning,Benzinga reports. Chardan Capital currently has a $6.00 price objective on the stock. Several other equities research analysts have also commented on GANX. Scotiabank assumed coverage on Gain Therapeutics in a research note on […]
Chardan Capital restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a report published on Friday morning,Benzinga reports. Chardan Capital currently has a $6.00 price objective on the stock. Several other equities research analysts have also commented on GANX. Scotiabank assumed coverage on Gain Therapeutics in a research note on […]
